ReviewMolecular medicine reports2026
From cell to disease: Regulatory networks and mechanisms of super‑enhancers in aging (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is accompanied by a gradual loss of cellular function and systemic weakening of the homeostasis of multiple tissues, leading to a variety of age‑related diseases and eventual mortality. Super‑enhancers are a distinct class of cis‑regulatory elements with strong transcriptional activation properties; they are bound by a large number of key transcription factors and cofactors, and possess distinct characteristic modification marks of enhancers. The past decade has seen an exponential growth in the field of super‑enhancer research, partly because of the strong transcriptional activity of super‑enhancers. Super‑enhancers are notably activated in response to aging or aging‑related factors, and serve a pivotal role in aging and aging‑related diseases by modulating key biological processes, including cell proliferation, differentiation and senescence. In the present review, the changes in super‑enhancers under aging‑related stimuli are initially discussed. The mechanistic contributions of super‑enhancers to cellular senescence from the perspective of DNA damage and mitochondrial dysfunction, two hallmarks of aging, are then systematically summarized. Furthermore, the pathogenic involvement of super‑enhancer dysregulation in specific age‑related disorders, including atherosclerosis and type Ⅱ diabetes, is explored, highlighting the potential of super‑enhancers as therapeutic targets. Finally, the current challenges and prospects of super‑enhancers within the context of aging biology are discussed, aiming to provide novel theoretical guidance for the treatment of age‑associated diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.